Sugemalimab plus chemotherapy versus chemotherapy for advanced gastric cancer in China: a cost-effectiveness analysis.

ABSTRACT: This study aimed to evaluate the cost-effectiveness of sugemalimab plus chemotherapy compared to chemotherapy in the treatment of advanced gastric cancer in China. A Markov model of partitioned survival was developed based on the GEMSTONE-303 Phase III clinical trial evaluating sugemalimab in combination with chemotherapy for advanced gastric cancer. The model incorporates three distinct health states: progression-free survival, disease progression, and death.The transition probabilities between these states and drug treatment and adverse reaction datas were derived from the clinical trial.Direct medical costs were obtained from local sources, and utility values were derived from published literature. Costs and outcomes were projected over a lifetime horizon and discounted at an annual rat

SUBMITTER: Lin X 

PROVIDER: S-EPMC12480027 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature